Chinese say they've discovered cancer medicine

A new bar promises to prevent cancer from spreading to other organs. Another can cure blood cancer. The third could use the immune system to kill tumors, the BBC writes. All three of them have shown promising results and need only one step to be approved for use even [...]
A new bar promises to prevent cancer from spreading to other organs. Another can cure blood cancer. The third could use the immune system to kill tumors, the BBC writes.
All three of them have shown promising results and need only one step to be approved for use in the United States as well. But drugs also have something in common: They were created in China.
For years the China drug industry concentrated on replacing Western medicine.
The creation of new drugs was a tiresome process that took a long time.
Companies initially thought that investment in millions of dollars in research and development was dangerous and remained in businesses that brought secure revenue.
This country is now trying to play a bigger role in the global drug industry. Millions of people in China have cancer or diabetes, and the government has made a national priority in drug innovation.
However, discoveries in this field in China are still in its early stages compared with the vast industry. Some experts say, however, it is only a matter of time until medical companies manage to stand by the giants like Pfizer and AstraZeneca.
The last time China produced a new drug for the global pharmaceutical industry was in 1979, when Chinese scientist Tu Youyo discovered the artery after Mao Zedong asked to find a cure for malaria.
But globally it was not recognized until later, since Swiss pharmacist Novatimes brought this Chinese discovery to the surface and began production in 1990.
Mrs. Tu was awarded the Nobel Prize in 2015.
Despite optimism, Chinese pharmaceutical companies that want to emerge in other countries still struggle. The competition between producers in large countries like the United States is very strong and Chinese companies are stuck because of the financial tools needed for research.












